Annual report
4578.TEDINET S100VJ30
Period2024-01-01 → 2024-12-31
Filed2025-03-31
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 150
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.33T | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.02T | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥1.74T | 2022-01-01 → 2022-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.50T | 2021-01-01 → 2021-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.42T | 2020-01-01 → 2020-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥323.6bn | 2024-01-01 → 2024-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥139.6bn | 2023-01-01 → 2023-12-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥335.9bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥142.7bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥173.0bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥163.6bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥190.0bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥343.1bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥121.6bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥133.9bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥125.5bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥148.1bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥347.3bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥125.5bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss IFRS |
| Total assets | ¥3.74T | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.36T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.10T | at 2022-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥2.82T | at 2021-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥2.63T | at 2020-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥961.1bn | at 2024-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥924.9bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥2.78T | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.44T | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.26T | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥2.73T | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.39T | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.23T | at 2022-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥2.01T | at 2021-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.85T | at 2020-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥426.2bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥513.3bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥471.6bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥410.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥356.9bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥354.6bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥283.2bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥211.8bn | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥228.9bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥232.8bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥265.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥190.5bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥81.6bn | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥95.3bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥99.9bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥189.4bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥60.3bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥95.5bn | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥95.8bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥104.9bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥633.76 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥224.1 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥246.8 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥231.32 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥273.15 | 2020-01-01 → 2020-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥246.78 | 2022-01-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥231.15 | 2021-01-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥272.35 | 2020-01-01 → 2020-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥5,089.58 | at 2024-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥4,410.8 | at 2023-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥4,100.84 | at 2022-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥3,707.64 | at 2021-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥3,415.54 | at 2020-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 73.1% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.2% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.7% | at 2022-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.3% | at 2021-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 70.5% | at 2020-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 13.4% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 5.3% | 2023-01-01 → 2023-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.3% | 2022-01-01 → 2022-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.5% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.2% | 2020-01-01 → 2020-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 35,338 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 34,388 | at 2023-12-31 | Cons. | Number of employees |
| Employees | 33,482 | at 2022-12-31d | Cons. | Number of employees |
| Employees | 33,226 | at 2021-12-31d | Cons. | Number of employees |
| Employees | 33,151 | at 2020-12-31d | Cons. | Number of employees |
| Revenue | ¥118.0bn | 2024-01-01 → 2024-12-31 | Standalone | Operating revenue1 |
| Revenue | ¥82.4bn | 2023-01-01 → 2023-12-31 | Standalone | Operating revenue1 |
| Revenue | ¥57.0bn | 2022-01-01 → 2022-12-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥115.0bn | 2021-01-01 → 2021-12-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥102.7bn | 2020-01-01 → 2020-12-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥102.9bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Operating income | ¥69.0bn | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Ordinary income | ¥105.0bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥70.0bn | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥46.4bn | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥104.8bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥93.5bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥105.0bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥70.0bn | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Net income | ¥106.4bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥71.0bn | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | ¥47.4bn | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥106.0bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥94.4bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.38T | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥1.21T | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥1.27T | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.25T | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.21T | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥309.6bn | at 2024-12-31 | Standalone | Liabilities |
| Total liabilities | ¥132.5bn | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.07T | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.08T | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.06T | at 2022-12-31d | Standalone | Net assets |
| Net assets / equity | ¥1.07T | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.02T | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥130.4bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥86.4bn | at 2023-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥196.52 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥130.92 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.37 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.5 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥174.03 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥120 | 2024-01-01 → 2024-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥110 | 2023-01-01 → 2023-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2022-01-01 → 2022-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2021-01-01 → 2021-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2020-01-01 → 2020-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,997.67 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,989.83 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,959.51 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,970.44 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,875.15 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 77.6% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.1% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.6% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.6% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.2% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.9% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2023-01-01 → 2023-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.4% | 2022-01-01 → 2022-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.2% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.5% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 552,024,717 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 557,835,617 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 557,835,617 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 557,835,617 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 557,835,617 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 183 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 151 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 147 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 137 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 111 | at 2020-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 61
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-01-01 → 2024-12-31 | ¥9.9bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥3.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥3.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥51.8bn |
| Consumer Productsreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥3.6bn |
| Consumer Productsreportable segment | employees | at 2024-12-31 | 604 pure |
| Consumer Productsreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥33.8bn |
| Consumer Productsreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥33.8bn |
| Consumer Productsreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥7m |
| Consumer Productsreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥23.0bn |
| Nutraceuticalsreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥54.2bn |
| Nutraceuticalsreportable segment | employees | at 2024-12-31 | 9166 pure |
| Nutraceuticalsreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥557.0bn |
| Nutraceuticalsreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥557.0bn |
| Nutraceuticalsreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥37m |
| Nutraceuticalsreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥59.8bn |
| Otherreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥7.7bn |
| Otherreportable segment | employees | at 2024-12-31 | 2756 pure |
| Otherreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥113.7bn |
| Otherreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥110.1bn |
| Otherreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥3.6bn |
| Otherreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥7.5bn |
| Pharmaceuticalsreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥252.0bn |
| Pharmaceuticalsreportable segment | employees | at 2024-12-31 | 21421 pure |
| Pharmaceuticalsreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥1.63T |
| Pharmaceuticalsreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥1.63T |
| Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥285.1bn |
| —segment total | capex | 2024-01-01 → 2024-12-31 | ¥317.4bn |
| —segment total | employees | at 2024-12-31 | 33947 pure |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥2.33T |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥2.33T |
| —segment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥3.6bn |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥375.4bn |
| Reconciling Itemsreconciling | capex | 2023-01-01 → 2023-12-31 | ¥12.5bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-12-31 | −¥3.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-12-31 | −¥3.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-12-31 | −¥50.7bn |
| Consumer Productsreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥3.8bn |
| Consumer Productsreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥37.1bn |
| Consumer Productsreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥37.1bn |
| Consumer Productsreportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥14m |
| Consumer Productsreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥12.1bn |
| Nutraceuticalsreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥105.8bn |
| Nutraceuticalsreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥483.5bn |
| Nutraceuticalsreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥483.3bn |
| Nutraceuticalsreportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥138m |
| Nutraceuticalsreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥34.2bn |
| Otherreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥5.4bn |
| Otherreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥110.2bn |
| Otherreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥107.0bn |
| Otherreportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥3.2bn |
| Otherreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥278m |
| Pharmaceuticalsreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥83.6bn |
| Pharmaceuticalsreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥1.39T |
| Pharmaceuticalsreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥1.39T |
| Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥143.7bn |
| —segment total | capex | 2023-01-01 → 2023-12-31 | ¥198.5bn |
| —segment total | revenue | 2023-01-01 → 2023-12-31 | ¥2.02T |
| —segment total | revenue external | 2023-01-01 → 2023-12-31 | ¥2.02T |
| —segment total | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥3.3bn |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | ¥190.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,346
| Item | Context | Value | Unit |
|---|---|---|---|
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration_ReportableSegmentsMember | 33614000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration | 33614000000 | JPY |
| Impairment losses pl IFRS | CurrentYearDuration_jpcrp030000-asr_E21183-000PharmaceuticalsReportableSegmentMember | 119682000000 | JPY |
| Impairment losses pl IFRS | CurrentYearDuration_jpcrp030000-asr_E21183-000NutraceuticalsReportableSegmentMember | 5735000000 | JPY |
| Impairment losses pl IFRS | CurrentYearDuration_jpcrp030000-asr_E21183-000ConsumerProductsReportableSegmentMember | 454000000 | JPY |
| Impairment losses pl IFRS | CurrentYearDuration_jpcrp030000-asr_E21183-000OtherReportableSegmentMember | 121000000 | JPY |
| Impairment losses pl IFRS | CurrentYearDuration_ReportableSegmentsMember | 125993000000 | JPY |
| Impairment losses pl IFRS | CurrentYearDuration_ReconcilingItemsMember | 47000000 | JPY |
| Impairment losses pl IFRS | CurrentYearDuration | 126040000000 | JPY |
| Capital expenditures IFRS | CurrentYearDuration_jpcrp030000-asr_E21183-000PharmaceuticalsReportableSegmentMember | 252004000000 | JPY |
| Capital expenditures IFRS | CurrentYearDuration_jpcrp030000-asr_E21183-000NutraceuticalsReportableSegmentMember | 54170000000 | JPY |
| Capital expenditures IFRS | CurrentYearDuration_jpcrp030000-asr_E21183-000ConsumerProductsReportableSegmentMember | 3606000000 | JPY |
| Capital expenditures IFRS | CurrentYearDuration_jpcrp030000-asr_E21183-000OtherReportableSegmentMember | 7659000000 | JPY |
| Capital expenditures IFRS | CurrentYearDuration_ReportableSegmentsMember | 317441000000 | JPY |
| Capital expenditures IFRS | CurrentYearDuration_ReconcilingItemsMember | 9883000000 | JPY |
| Capital expenditures IFRS | CurrentYearDuration | 327325000000 | JPY |
| Merchandise and finished goods ca IFRS | Prior1YearInstant | 124342000000 | JPY |
| Merchandise and finished goods ca IFRS | CurrentYearInstant | 136704000000 | JPY |
| Work in process ca IFRS | Prior1YearInstant | 46408000000 | JPY |
| Work in process ca IFRS | CurrentYearInstant | 62518000000 | JPY |
| Raw materials ca IFRS | Prior1YearInstant | 73544000000 | JPY |
| Raw materials ca IFRS | CurrentYearInstant | 92829000000 | JPY |
| Production supplies ca IFRS | Prior1YearInstant | 5285000000 | JPY |
| Production supplies ca IFRS | CurrentYearInstant | 6238000000 | JPY |
| Inventories ca IFRS | Prior1YearInstant | 249581000000 | JPY |
| Inventories ca IFRS | CurrentYearInstant | 298292000000 | JPY |
| Buildings and structures acquisition cost IFRS | Prior1YearInstant | 611046000000 | JPY |
| Machinery and vehicles acquisition cost IFRS | Prior1YearInstant | 526442000000 | JPY |
| Tools furniture and fixtures acquisition cost IFRS | Prior1YearInstant | 134800000000 | JPY |
| Land acquisition cost IFRS | Prior1YearInstant | 98356000000 | JPY |
| Construction in progress acquisition cost IFRS | Prior1YearInstant | 61865000000 | JPY |
| Property plant and equipment acquisition cost IFRS | Prior1YearInstant | 1432512000000 | JPY |
| Buildings and structures acquisition cost IFRS | CurrentYearInstant | 659452000000 | JPY |
| Machinery and vehicles acquisition cost IFRS | CurrentYearInstant | 561553000000 | JPY |
| Tools furniture and fixtures acquisition cost IFRS | CurrentYearInstant | 142198000000 | JPY |
| Land acquisition cost IFRS | CurrentYearInstant | 100693000000 | JPY |
| Construction in progress acquisition cost IFRS | CurrentYearInstant | 91824000000 | JPY |
| Property plant and equipment acquisition cost IFRS | CurrentYearInstant | 1555721000000 | JPY |
| Buildings and structures accumulated depreciation and impairment losses IFRS | Prior1YearInstant | -368676000000 | JPY |
| Machinery and vehicles accumulated depreciation and impairment losses IFRS | Prior1YearInstant | -389792000000 | JPY |
| Tools furniture and fixtures accumulated depreciation and impairment losses IFRS | Prior1YearInstant | -110173000000 | JPY |
| Land accumulated impairment losses IFRS | Prior1YearInstant | -8677000000 | JPY |
| Construction in progress accumulated impairment losses IFRS | Prior1YearInstant | -1834000000 | JPY |
| Property plant and equipment accumulated depreciation and impairment losses IFRS | Prior1YearInstant | -879153000000 | JPY |
| Buildings and structures accumulated depreciation and impairment losses IFRS | CurrentYearInstant | -387679000000 | JPY |
| Machinery and vehicles accumulated depreciation and impairment losses IFRS | CurrentYearInstant | -412394000000 | JPY |
| Tools furniture and fixtures accumulated depreciation and impairment losses IFRS | CurrentYearInstant | -114977000000 | JPY |
| Land accumulated impairment losses IFRS | CurrentYearInstant | -8854000000 | JPY |
| Construction in progress accumulated impairment losses IFRS | CurrentYearInstant | -3271000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |